Article
A Novavax Bull Cuts His Price Target, Citing 'Challenged National Sentiment' Towards COVID-19 V
Rating:
0.0
Views:
72
Likes:
1
Library:
1
The race to be first to market with a COVID-19 vaccine is far from over. However, Novavax (NVAX), so far, is the clear winner – at least on Wall Street. Shares have surged by a barely believable 2,236% year-to-date, as investors have cheered the progress of NVX-CoV2373, the company's COVID-19 vaccine candidate. However, as with […]
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value